Tocilizumab is effective in a familial Mediterranean fever patient complicated with histologically proven recurrent fasciitis and myositis.
Sasebo Chuo Hospital, Nagasaki, Japan.|Unit of Translational Medicine, Department of Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Masataka
M
Umeda
Sasebo Chuo Hospital, Nagasaki, Japan.
Toshiyuki
T
Aramaki
Isahaya General Hospital, Nagasaki, Japan.
Keita
K
Fujikawa
Unit of Translational Medicine, Department of Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Naoki
N
Iwamoto
Unit of Translational Medicine, Department of Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Kunihiro
K
Ichinose
Sasebo Chuo Hospital, Nagasaki, Japan.
Kaoru
K
Terada
Sasebo Chuo Hospital, Nagasaki, Japan.
Gou
G
Takeo
Sasebo Chuo Hospital, Nagasaki, Japan.
Nobuhisa
N
Yonemitsu
Sasebo Chuo Hospital, Nagasaki, Japan.
Yukitaka
Y
Ueki
Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Nagasaki, Japan.
Kiyoshi
K
Migita
Unit of Translational Medicine, Department of Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Atsushi
A
Kawakami
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001706:Biopsy; D010505:Familial Mediterranean Fever / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D005208:Fasciitis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009220:Myositis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D012008:Recurrence; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; C502936:tocilizumab